(ENOV) Enovis - Overview
Stock: Orthopedic Braces, Joint Implants, Surgical Tools, Rehab Devices
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 57.8% |
| Relative Tail Risk | -8.03% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.18 |
| Alpha | -70.69 |
| Character TTM | |
|---|---|
| Beta | 1.410 |
| Beta Downside | 1.356 |
| Drawdowns 3y | |
|---|---|
| Max DD | 67.26% |
| CAGR/Max DD | -0.43 |
Description: ENOV Enovis January 15, 2026
Enovis Corp (NYSE:ENOV) is a U.S.-based medical-technology firm that develops clinically differentiated orthopedic and reconstructive solutions for both domestic and international markets. The business is split into two segments: Prevention & Recovery, which supplies bracing, therapy devices, bone-growth stimulators, compression garments and related physical-therapy products; and Reconstructive, which designs and sells joint-replacement implants (hip, knee, shoulder, elbow, foot/ankle, finger) and surgical productivity tools under the ESAB and DJO brands.
Key operating metrics (FY 2023) show total revenue of $1.62 billion, with the Prevention & Recovery segment contributing roughly 38 % and the Reconstructive segment 62 %. Gross margin improved to 48 % year-over-year, driven by higher implant pricing and cost-efficiency initiatives. R&D intensity remains around 6 % of revenue, reflecting ongoing investment in next-generation biomaterials and digital therapy platforms.
Sector drivers that materially affect Enovis include the aging U.S. population (U.S. Census projects 21 % of Americans will be 65+ by 2030), rising prevalence of osteoarthritis, and the shift toward outpatient joint-replacement procedures, which compresses implant pricing but expands procedure volume. Medicare’s bundled-payment reforms and potential changes to reimbursement for bone-growth stimulators add regulatory uncertainty that can swing segment profitability.
For a data-rich, quantitative deep-dive on ENOV’s valuation sensitivities and peer comparison, the ValueRay platform offers a concise, model-backed overview worth exploring.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -1.37b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 1.63 > 1.0 |
| NWC/Revenue: 31.55% < 20% (prev 33.61%; Δ -2.06% < -1%) |
| CFO/TA 0.05 > 3% & CFO 217.1m > Net Income -1.37b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (56.8m) vs 12m ago 2.02% < -2% |
| Gross Margin: 58.36% > 18% (prev 0.57%; Δ 5779 % > 0.5%) |
| Asset Turnover: 44.74% > 50% (prev 36.07%; Δ 8.67% > 0%) |
| Interest Coverage Ratio: -26.36 > 6 (EBITDA TTM -989.6m / Interest Expense TTM 48.4m) |
Altman Z'' -1.81
| A: 0.16 (Total Current Assets 1.28b - Total Current Liabilities 575.4m) / Total Assets 4.43b |
| B: -0.21 (Retained Earnings -946.9m / Total Assets 4.43b) |
| C: -0.26 (EBIT TTM -1.28b / Avg Total Assets 4.99b) |
| D: -0.42 (Book Value of Equity -1.02b / Total Liabilities 2.41b) |
| Altman-Z'' Score: -1.81 = D |
Beneish M -3.46
| DSRI: 0.97 (Receivables 431.8m/400.2m, Revenue 2.23b/2.00b) |
| GMI: 0.97 (GM 58.36% / 56.83%) |
| AQI: 0.84 (AQ_t 0.59 / AQ_t-1 0.70) |
| SGI: 1.12 (Revenue 2.23b / 2.00b) |
| TATA: -0.36 (NI -1.37b - CFO 217.1m) / TA 4.43b) |
| Beneish M-Score: -3.46 (Cap -4..+1) = AA |
What is the price of ENOV shares?
Over the past week, the price has changed by +6.29%, over one month by -15.55%, over three months by -27.45% and over the past year by -50.53%.
Is ENOV a buy, sell or hold?
- StrongBuy: 7
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ENOV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 45.1 | 97.7% |
| Analysts Target Price | 45.1 | 97.7% |
| ValueRay Target Price | 16.1 | -29.4% |
ENOV Fundamental Data Overview February 03, 2026
P/S = 0.5644
P/B = 0.6427
P/EG = 1.8989
Revenue TTM = 2.23b USD
EBIT TTM = -1.28b USD
EBITDA TTM = -989.6m USD
Long Term Debt = 1.34b USD (from longTermDebt, last quarter)
Short Term Debt = 44.0m USD (from shortTermDebt, last quarter)
Debt = 1.44b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.41b USD (from netDebt column, last quarter)
Enterprise Value = 2.67b USD (1.26b + Debt 1.44b - CCE 33.6m)
Interest Coverage Ratio = -26.36 (Ebit TTM -1.28b / Interest Expense TTM 48.4m)
EV/FCF = 117.2x (Enterprise Value 2.67b / FCF TTM 22.8m)
FCF Yield = 0.85% (FCF TTM 22.8m / Enterprise Value 2.67b)
FCF Margin = 1.02% (FCF TTM 22.8m / Revenue TTM 2.23b)
Net Margin = -61.22% (Net Income TTM -1.37b / Revenue TTM 2.23b)
Gross Margin = 58.36% ((Revenue TTM 2.23b - Cost of Revenue TTM 929.9m) / Revenue TTM)
Gross Margin QoQ = 59.92% (prev 59.29%)
Tobins Q-Ratio = 0.60 (Enterprise Value 2.67b / Total Assets 4.43b)
Interest Expense / Debt = 1.45% (Interest Expense 20.8m / Debt 1.44b)
Taxrate = 21.0% (US default 21%)
NOPAT = -1.01b (EBIT -1.28b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.22 (Total Current Assets 1.28b / Total Current Liabilities 575.4m)
Debt / Equity = 0.71 (Debt 1.44b / totalStockholderEquity, last quarter 2.02b)
Debt / EBITDA = -1.42 (negative EBITDA) (Net Debt 1.41b / EBITDA -989.6m)
Debt / FCF = 61.83 (Net Debt 1.41b / FCF TTM 22.8m)
Total Stockholder Equity = 2.44b (last 4 quarters mean from totalStockholderEquity)
RoA = -27.39% (Net Income -1.37b / Total Assets 4.43b)
RoE = -55.92% (Net Income TTM -1.37b / Total Stockholder Equity 2.44b)
RoCE = -33.70% (EBIT -1.28b / Capital Employed (Equity 2.44b + L.T.Debt 1.34b))
RoIC = -26.43% (negative operating profit) (NOPAT -1.01b / Invested Capital 3.81b)
WACC = 5.79% (E(1.26b)/V(2.70b) * Re(11.11%) + D(1.44b)/V(2.70b) * Rd(1.45%) * (1-Tc(0.21)))
Discount Rate = 11.11% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.99%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈22.8m ; Y1≈14.9m ; Y5≈6.82m
Fair Price DCF = N/A (negative equity: EV 217.3m - Net Debt 1.41b = -1.19b; debt exceeds intrinsic value)
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: 7.85 | EPS CAGR: -40.52% | SUE: -4.0 | # QB: 0
Revenue Correlation: 21.44 | Revenue CAGR: -15.30% | SUE: 2.01 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.79 | Chg30d=+0.026 | Revisions Net=+0 | Analysts=10
EPS next Year (2026-12-31): EPS=3.42 | Chg30d=-0.032 | Revisions Net=-1 | Growth EPS=+6.7% | Growth Revenue=+4.5%